Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study
Overview
- Phase
- Not Applicable
- Intervention
- prednisolone 1%
- Conditions
- Primary Open Angle Glaucoma
- Sponsor
- Queen's University
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Intraocular pressure lowering effect
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.
Detailed Description
Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one of prednisolone 1%, ketorolac 0.5% or artificial tears four times a day for 5 days following administration of the laser treatment. The IOP will be measured at various time points following SLT: 1 hour, 2 days, 1 week, 1 month, 3 months, 6 months, and 1 year.
Investigators
Dr. Robert Campbell
Assistant Professor
Queen's University
Eligibility Criteria
Inclusion Criteria
- •primary open angle glaucoma, pseudo exfoliation glaucoma
Exclusion Criteria
- •previous incisional glaucoma surgery
Arms & Interventions
1
Prednisolone 1% eye drop
Intervention: prednisolone 1%
2
ketorolac 0.5% eye drop
Intervention: ketorolac 0.5%
3
Artificial Tears (methyl cellulose eye drop)
Intervention: Artificial Tears (Methyl cellulose drops)
Outcomes
Primary Outcomes
Intraocular pressure lowering effect
Time Frame: 1 hour, 2 days, 1 month, 3 months, 6 months and 1 year
Secondary Outcomes
- intraocular pressure elevation(1 hour, 2 days, 1 month)